share_log

Faron Pharmaceuticals Oy (LON:FARN) Share Price Passes Above 50 Day Moving Average of $176.78

Faron Pharmaceuticals Oy (LON:FARN) Share Price Passes Above 50 Day Moving Average of $176.78

Faron PharmPharmticals Oy(伦敦代码:FARN)股价突破50日移动均线176.78美元
Defense World ·  2022/11/16 05:01

Faron Pharmaceuticals Oy (LON:FARN – Get Rating) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 176.78 ($2.08) and traded as high as GBX 239 ($2.81). Faron Pharmaceuticals Oy shares last traded at GBX 232.50 ($2.73), with a volume of 30,156 shares traded.

在周二的交易中,Faron PharmPharmticals Oy(LON:FARN-GET Rating)的股价超过了50日移动平均线。该股的50日移动均线为176.78英镑(合2.08美元),交易价格高达239英镑(合2.81美元)。Faron PharmPharmticals Oy的股票最后交易价格为232.50英镑(合2.73美元),成交量为30,156股。

Faron Pharmaceuticals Oy Stock Performance

Faron制药公司的股票表现

The company has a market capitalization of £143.53 million and a P/E ratio of -6.48. The business has a 50-day moving average of GBX 176.78 and a 200-day moving average of GBX 197.63. The company has a debt-to-equity ratio of 121.51, a current ratio of 1.70 and a quick ratio of 1.09.

该公司市值为1.4353亿GB,市盈率为-6.48。该业务的50日移动均线切入位在176.78英镑,200日移动均线切入位在197.63英镑。该公司的债务权益比率为121.51,流动比率为1.7,速动比率为1.09。

Faron Pharmaceuticals Oy Company Profile

Faron制药公司简介

(Get Rating)

(获取评级)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.

Faron PharmPharmticals Oy是一家临床阶段药物发现和开发公司。该公司开发了一系列基于免疫调节的专利候选药物,以满足未得到满足的需求,包括免疫肿瘤学、器官保护和再生医学。它的主要候选产品是Traumakine,一种静脉注射干扰素β-1a疗法,用于治疗急性呼吸窘迫综合征、新冠肺炎、急性肾损伤、心脏保护、实体器官移植和缺血再灌注损伤;以及Bexmarilimab,一种新的精密癌症免疫疗法候选药物,用于治疗实体瘤、非小细胞肺癌和血液系统恶性肿瘤。

Further Reading

进一步阅读

  • Power Integrations Stock Can Power Your Portfolio
  • Don't Chase Walmart Higher, Wait For Extra Low Prices
  • Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
  • Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
  • Three Penny Stocks Making Big Moves In November
  • 电源整合股票可以为您的投资组合提供动力
  • 不要追逐沃尔玛更高,等待超低价格
  • 家得宝的业绩(和机构)是劳氏的催化剂吗?
  • 安捷伦在下周第四季度报告发布前仍在买入区间
  • 三只细价股在11月大动干戈

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.

接受Faron制药Oy Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Faron PharmPharmticals Oy和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发